The Latest Cardiac and Vascular News
MARLBOROUGH, Mass., Dec. 11, 2018 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced that a jury in the United States (U.S.) District Court for the District of Delaware determined that the Boston Scientific U.S. patent 8,992,608 is valid and that Edwards Lifesciences’ Sapien 3™ Aortic Valve infringes this patent and that Edwards owes Boston Scientific infringement damages […]
IRVINE, Calif., Dec. 11, 2018 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, commented today on a federal jury’s decisions in patent litigation between Edwards and Boston Scientific: The jury awarded $35 million in damages to Boston Scientific for infringement of U.S. […]
SAN FRANCISCO – December 10, 2018 – Bay Labs, a medical technology company at the forefront of applying artificial intelligence (AI) to cardiovascular imaging, announced today a collaboration with Edwards Lifesciences focused on improving the detection of heart disease. The partnership involves multiple initiatives, including the development of new AI-powered […]
VANCOUVER, British Columbia–(BUSINESS WIRE)–According to a new series of reports by iData Research, the United States cardiac surgery device market is valued at $5.7 billion USD and is forecast to exceed $10 billion by 2024. The largest segment of the cardiac surgery market is the transcatheter heart valve replacement (THVR) […]
IRVINE, Calif., Nov. 16, 2018 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced it has received CE Mark for the SAPIEN 3 Ultra system for transcatheter aortic valve replacement in severe, symptomatic aortic stenosis patients. “The SAPIEN 3 Ultra […]
IRVINE, Calif., Oct. 23, 2018 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today reported financial results for the quarter ended September 30, 2018. Third Quarter and Recent Highlights: Sales grew 10 percent; underlying1 sales grew 11 percent Global THVT sales grew 16 […]
MARLBOROUGH, Mass., Oct. 23, 2018 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced the District Court of Dusseldorf, Germany has determined that Edwards Lifesciences Corporation’s Sapien 3 Ultra™ device infringed a patent – established by Symetis SA, a subsidiary of Boston Scientific – specific to the fabric used on the […]
IRVINE, Calif., Oct. 8, 2018 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that it has commenced the U.S. pivotal trial that will study its self-expanding CENTERA transcatheter valve for severe, symptomatic aortic stenosis (AS) patients at intermediate […]
IRVINE, Calif., Sept. 26, 2018 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE :EW ), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, announced at a 60th anniversary educational event that the Every Heartbeat Matters initiative has exceeded the goal to impact the global burden of heart valve disease […]
IRVINE, Calif., July 26, 2018 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today reported financial results for the quarter ended June 30, 2018. Second Quarter and Recent Highlights: Sales grew 12 percent; underlying1 sales grew 10 percent Global THVT sales grew […]
